Medical News Today -
13 Dec 2013 12:00
Adaptimmune has announced the release of interim results from a Phase I/II clinical trial using patients' own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results at the annual meeting of the American Society of Hematology (ASH).The clinical trial was designed as a single arm open label study where patients are given standard of care (autologous stem cell transplant).
Share this Article